Back
Crinetics Pharmaceuticals, Inc. (CRNX)
PharmaceuticalsCRNX · NASDAQ NMS - GLOBAL MARKET · USD
New to investing? How to read this page →$84.85
+0.07%Weekly undervalued picks
Price · 1 year
Loading live analysis…
Loading analysis…
Intrinsic Investor is for research and education only. Not financial advice.
Key metrics
EPS
$-4.95
ROE
-39.2%
Gross margin
0.0%
Debt/Equity
3.74x
Revenue growth
2873.4%
P/B ratio
Beta
Forward P/E
Crinetics Pharmaceuticals, Inc. — company intelligence
Earnings surprises
Q2 2026$-1.14 vs $-1.23 est+7.6%
Q1 2026$-1.23 vs $-1.26 est+2.5%
Q4 2025$-1.29 vs $-1.39 est+7.5%
Q3 2025$-1.38 vs $-1.28 est-7.8%
Analyst consensus · 21 analysts
7 Buy14 Hold0 Sell
Updated Aug 10, 2026
Insider activity · 90 days
14 buys3 sellsnet +99,685 shares
Struthers Richard Scottother 6,542 · Aug 7, 2026
Struthers Richard Scottother 4,995 · Aug 7, 2026
Struthers Richard Scottother 4,422 · Aug 7, 2026
Recent SEC filings
8-K — Material event reportAug 19, 2026
8-K — Material event reportAug 14, 2026
4 — Insider transaction reportAug 11, 2026
Latest news
Top 3 Health Care Stocks That May Implode In August — Benzinga · 1w ago
Crinetics Pharmaceuticals (CRNX) On Vertex Deal Optimism And Results Looks Nearly Fully Valued — Yahoo · 3w ago
Vertex Pharmaceuticals' Solid Q2, Raised Outlook Underscore Core Business Strength, RBC Says — Yahoo · 3w ago
Vertex Pharmaceuticals Incorporated Q2 2026 Earnings Call Summary — Yahoo · 3w ago
AI Valuation Narrative
Generates a short bull / bear / catalyst summary from the analytics we already computed. No target prices. Research tool, not investment advice.
Explore more
Peers & similar stocks
Quick links to related tickers for research.
Weekly undervalued picks
Get 3 new value ideas and the fair-value math behind them every week. One email, unsubscribe anytime.
Free. No spam. We only email once per week.
Data is provided "as-is" and may be delayed or incomplete. Intrinsic Investor is for education only and is not investment advice.